Skip to content

Serotonin research published in 2022

86 studies whose primary subject is serotonin were published in 2022, up from 59 in 2021. Newest first. Back to the serotonin overview

Studies

(+)-Catharanthine and (-)-18-methoxycoronaridine induce antidepressant-like activity in mice by differently recruiting serotonergic and norepinephrinergic neurotransmission.

European Journal of Pharmacology December 19, 2022 Hugo R Arias, Philippe De Deurwaerdère, Ali El-Kasaby et al.

The antidepressant-like activity of (+)-catharanthine and (-)-18-methoxycoronaridine [(-)-18-MC] was studied in male and female mice using forced swim (FST) and tail suspension tests (TST). The underlying molecular mechanism was assessed by electrophysiological, radioligand, and functional experiments. The FST results showed that acute administration (40 mg/kg) of (+)-catharanthine or (-)-18-MC...

Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs

ACS Chemical Neuroscience December 15, 2022 Michael J. Cunningham, Hailey A. Bock, Inis C. Serrano et al. 65 citations

Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. Ariadne has been tested in humans including clinical trials at Bristol-Myers Company that indicate a lack of hallucinogenic...

Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines

Neuropharmacology December 15, 2022 David J Heal, Jane Gosden, Sharon L. Smith et al. 18 citations

Research on classical psychedelics (psilocybin, LSD and DMT) and entactogen, MDMA, has produced a renaissance in the search for more effective drugs to treat psychiatric, neurological and various peripheral disorders. Psychedelics and entactogens act though interaction with 5-HT2A and other serotonergic receptors and/or monoamine reuptake transporters. 5-HT, which serves as a neurotransmitter...

Sleep-like state during wakefulness induced by psychedelic 5-MeO-DMT in mice

bioRxiv (Cold Spring Harbor Laboratory) December 11, 2022 Benjamin J. B. Bréant, José Prius-Mengual, David M. Bannerman et al. 5 citations preprint

Abstract Psychedelics lead to profound changes in subjective experience and behaviour, which are typically conceptualised in psychological terms rather than corresponding to an altered brain state or a distinct state of arousal. Here, we performed chronic electrophysiological recordings from the cortex concomitant with pupillometry in freely moving adult male mice following an injection of a...

Effects of a single dose of psilocybin on cytokines, chemokines and leptin in rat serum

Journal of Psychedelic Studies December 7, 2022 Geoffrey M. Bove, David J. Mokler 8 citations

Abstract Background and Aims The hallucinogenic drug psilocybin is being widely tested in humans for the treatment of psychiatric disorders. Psilocybin and other psychedelics are proposed to work through serotonin 2a (5-HT2a) receptors, which are tightly linked to immune function. The purpose of the present study was to assess the effects of a single dose of psilocybin on a panel of cytokines,...

Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice

Pharmacology, Biochemistry, and Behavior December 5, 2022 Youge Qu, Lijia Chang, Li Ma et al. 42 citations

Classical psychedelics with 5-hydroxytryptamine-2A receptor (5-HT2AR) agonism have rapid antidepressant actions in patients with depression. However, there is an ongoing debate over the role of 5-HT2AR in the antidepressant-like actions of psychedelics. In this study, we compared the effects of DOI (2,5-dimethoxy-4-iodoamphetamine: a hallucinogenic psychedelic drug with potent 5-HT2AR agonism),...

Psychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice

International Journal of Molecular Sciences December 4, 2022 Mireia Medrano, An Buckinx, Ilse Smolders et al. 11 citations

Serotoninergic psychedelics such as psilocybin have been reported to elicit a long-lasting reduction in depressive symptoms. Although the main target for serotoninergic psychedelics, serotonin type 2A receptor (5-HT2A), has been established, the possible mechanism of the antidepressant action of psychedelics remains unknown. Using the mouse forced swim test model, we examined whether the...

Psychedelic-Assisted Therapy for People with Eating Disorders.

Current Psychiatry Reports December 1, 2022 Natalie Gukasyan, Colleen C Schreyer, Roland R. Griffiths et al. 29 citations

A growing body of research suggests psychedelic-assisted therapy (PAT) may be safe and effective for a variety of mental health conditions. Among these, eating disorders have been a recent target of interest. This review provides an up-to-date summary of the potential mechanisms and use of PAT in people diagnosed with eating disorders, with a focus on anorexia nervosa. Classic psychedelics may...

4-Isobutylmethcathinone—A Novel Synthetic Cathinone with High In Vitro Cytotoxicity and Strong Receptor Binding Preference of Enantiomers

Pharmaceuticals November 30, 2022 Martin Paškan, Silvie Rimpelová, Vladimíra Svobodová Pavlíčková et al. 9 citations

New psychoactive substances and among them synthetic cathinones represent a significant threat to human health globally. However, within such a large pool of substances derived from a natural compound ((S)-cathinone), substances with important pharmaceutical uses can be identified, as already documented by bupropione. Therefore, this work aimed to find a synthetic pathway for a novel synthetic...

DOI: 10.3390/ph15121495 (opens in new tab) Serotonin Cathinone Cytotoxicity Enantiomer +7

Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications

International Journal of Molecular Sciences November 16, 2022 Orr Shahar, Alexander Botvinnik, Noam Esh-Zuntz et al. 60 citations

There is increasing interest in the therapeutic potential of psilocybin. In rodents, the serotonin precursor, 5-hydroxytryptophan (5-HTP) and psilocybin induce a characteristic 5-HT2A receptor (5-HT2AR)-mediated head twitch response (HTR), which is correlated with the human psychedelic trip. We examined the role of other serotonergic receptors and the trace amine -associated receptor 1 (TAAR1)...

DOI: 10.3390/ijms232214148 (opens in new tab) Full text (opens in new tab) Psilocybin 5-hydroxytryptophan 5-HT Receptor Serotonin antagonists +1

Psychedelic compounds directly excite 5-HT 2A Layer 5 Pyramidal Neurons in the Prefrontal Cortex through a 5-HT 2A Gq -mediated activation mechanism

bioRxiv (Cold Spring Harbor Laboratory) November 15, 2022 Gavin P. Schmitz, Yi-Ting Chiu, Gabriele M. König et al. 15 citations preprint

Summary Psilocin, the active compound in Psilocybe sp . mushrooms, is a serotonergic psychedelic that has recently gained renewed interest due to its potential as a therapeutic tool. Despite promising clinical findings, the underlying signaling mechanisms and brain region-specific effects of psilocin and other psychedelic drugs remain unclear. Psilocin, like other psychedelic compounds, is an...

Psilocybin in Treatment-Resistant Depression

New England Journal of Medicine November 2, 2022 Bertha K. Madras 36 citations

Depression ranks first among psychiatric disorders that dominate the global burden of disease, posing a substantial personal strain and economic drain on nations.1 At least 30 drugs are Food and Drug Administration (FDA)–approved to treat depression,2 yet a systematic review and meta-analysis of 22 antidepressants concluded that although they were more effective than placebo in adults with...

Structure–Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice

ACS Pharmacology & Translational Science November 2, 2022 Eline Pottie, Marilyn Naeem, Vamshikrishna Reddy Sammeta et al. 91 citations

4-Phosphoryloxy-N,N-dimethyltryptamine (psilocybin) is a naturally occurring tertiary amine found in many mushroom species. Psilocybin is a prodrug for 4-hydroxy-N,N-dimethyltryptamine (psilocin), which induces psychedelic effects via agonist activity at the serotonin (5-HT) 2A receptor (5-HT2A). Several other 4-position ring-substituted tryptamines are present in psilocybin-containing...

Serotonergic antidepressant use is associated with weaker psilocybin effects

October 28, 2022 Natalie Gukasyan, Roland R. Griffiths, David B. Yaden et al. 1 citation preprint

Background: Psilocybin is being studied for depression, but little is known about how it interacts with common antidepressants. Limited data suggests that psilocybin’s effects may be diminished by serotonergic antidepressants acutely and even after a medication washout period.Aims: To learn the extent to which serotonergic antidepressants may diminish psilocybin’s effects both concurrently and...

A mechanistic model of the neural entropy increase elicited by psychedelic drugs

Research Square October 26, 2022 Rubén Herzog, Pedro A. M. Mediano, Fernando E. Rosas et al. 6 citations preprint

Abstract Psychedelic drugs, including lysergic acid diethylamide (LSD) and other agonists of the serotonin 2A receptor (5HT2A-R), induce drastic changes in subjective experience, and provide a unique opportunity to study the neurobiological basis of consciousness. One of the most notable neurophysiological signatures of psychedelics, increased entropy in spontaneous neural activity, is thought...

DOI: 10.21203/rs.3.rs-2187775/v1 (opens in new tab) Serotonin Psychedelics: hallucinogens Entheogens Psychotropic drugs +16

Acute Mescaline Intoxication Followed by Catatonia

Archives of Psychiatry Research October 20, 2022 Din Duraković, Ante Silić, Vjekoslav Peitl et al. 1 citation

The paper deals with a case report of a 41-year-old man who in search of the meaning of life in a so-called “shamanic ritual” drank tea made from the San Pedro cactus as well as paste made of the same plant. The hallucinations were post poned and started after 9.5 hours caracterised by a psychotic reaction with symptoms of catatonia. He was admitted to our Department of Psychiatry where he was...

Mescaline: The forgotten psychedelic

Neuropharmacology October 14, 2022 Ian G Campbell, Ioanna A. Vamvakopoulou, Kelly A.d. Narine et al. 97 citations

The pharmacological mechanisms of mescaline are similar to those of other classical psychedelics, like psilocybin and lysergic acid diethylamide (LSD). Mescaline appears to be safe to consume, with most intoxications being mild and easily treatable. Improvement in mental well-being and its ability to overcome alcoholism render mescaline potentially beneficial in clinical settings. This article...

Ritualistic use of ayahuasca enhances a shared functional connectome identity with others

bioRxiv (Cold Spring Harbor Laboratory) October 11, 2022 Pablo Mallaroni, Natasha L. Mason, Lilian Kloft et al. 4 citations preprint

Abstract The knowledge that brain functional connectomes are both unique and reliable has enabled behaviourally relevant inferences at a subject level. However, it is unknown whether such “fingerprints” persist under altered states of consciousness. Ayahuasca is a potent serotonergic psychedelic which elicits a widespread dysregulation of functional connectivity. Used communally in religious...

The treatment of depression — searching for new ideas

Frontiers in Pharmacology October 7, 2022 Katarzyna Stachowicz, Magdalena Sowa-Kućma 48 citations

Depression is a severe mental health problem that affects people regardless of social status or education, is associated with changes in mood and behavior, and can result in a suicide attempt. Therapy of depressive disorders is based mainly on drugs discovered in the 1960s and early 1970s. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)...

DOI: 10.3389/fphar.2022.988648 (opens in new tab) Serotonin Monoaminergic Antidepressant Pharmacology +1

Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD.

Neuron October 5, 2022 Can Cao, Ximena Barros-Álvarez, Shicheng Zhang et al. 158 citations

Serotonin (5-hydroxytryptamine [5-HT]) 5-HT2-family receptors represent essential targets for lysergic acid diethylamide (LSD) and all other psychedelic drugs. Although the primary psychedelic drug effects are mediated by the 5-HT2A serotonin receptor (HTR2A), the 5-HT2B serotonin receptor (HTR2B) has been used as a model receptor to study the activation mechanisms of psychedelic drugs due to...